Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Voyager Therapeutics (VYGR) Leases (2019 - 2025)

Voyager Therapeutics (VYGR) has disclosed Leases for 7 consecutive years, with $28.5 million as the latest value for Q4 2025.

  • Quarterly Leases fell 14.61% to $28.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $28.5 million through Dec 2025, down 14.61% year-over-year, with the annual reading at $28.5 million for FY2025, 14.61% down from the prior year.
  • Leases hit $28.5 million in Q4 2025 for Voyager Therapeutics, down from $29.7 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $39.2 million in Q1 2024 to a low of $13.5 million in Q4 2023.
  • Historically, Leases has averaged $26.9 million across 5 years, with a median of $31.6 million in 2025.
  • Biggest five-year swings in Leases: tumbled 53.72% in 2022 and later surged 161.08% in 2024.
  • Year by year, Leases stood at $33.5 million in 2021, then crashed by 53.72% to $15.5 million in 2022, then fell by 12.75% to $13.5 million in 2023, then soared by 146.85% to $33.3 million in 2024, then fell by 14.61% to $28.5 million in 2025.
  • Business Quant data shows Leases for VYGR at $28.5 million in Q4 2025, $29.7 million in Q3 2025, and $31.0 million in Q2 2025.